Compare Recursion Pharmaceuticals Inc (RXRX) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Teladoc Health Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B), while Teladoc Health Inc trades at $5.54 (market cap $1.01B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.1× Teladoc Health Inc's market cap, and Recursion Pharmaceuticals Inc is more actively traded (30,789,535 versus 4,668,477). Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Teladoc Health Inc for 39 Days on average.
| RXRX | TDOC | |
|---|---|---|
Market Cap | $2.14B | $1.01B |
Volume | 30,789,535 | 4,668,477 |
Sector | Health | Health |
52-Week High | $6.79 | $9.72 |
52-Week Low | $2.84 | $4.47 |
Typical Hold Time | 22 Days | 39 Days |
Enterprise Value | $1.66B | $1.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
TDOC trades at $5.56, down 3.64% today, near multi-year lows with a bearish technical outlook. The stock shows mixed fundamentals with revenue stabilizing around $2.5B but persistent net losses, though improving from 2024's $1B loss to $200M in 2025. Valuation metrics appear attractive with P/S of 0.4 and EV/EBITDA of 5.9, while analyst consensus remains cautiously optimistic with a $8.83 price target.
The outlook remains challenged by ongoing losses and BetterHelp segment weakness, but potential exists if Integrated Care profitability improves and new CFO leadership executes effectively. Key risks include sustained negative cash flow, competitive pressures, and the ongoing SEC investigation highlighted in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
